43 results on '"Valim, Valéria"'
Search Results
2. Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases
3. Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose
4. Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients
5. Brazilian version of the “Primary Sjögren’s Syndrome - Quality of Life questionnaire (PSS-QoL)”: translation, cross-cultural adaptation and validation
6. Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study.
7. Brazilian version of the "Primary Sjögren's Syndrome - Quality of Life questionnaire (PSS-QoL)": translation, cross-cultural adaptation and validation.
8. Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2
9. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination
10. The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis.
11. EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE
12. Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study
13. Clinical risk factors for predicting anti-Sars-CoV-2 antibody immunoreactivity duration after mild COVID-19 infection
14. CARDIOVASCULAR RISK IN SJÖGREN S DISEASE FROM THE BRAZILIAN SJÖGREN S DISEASE REGISTRY (REBRAS)
15. HEALTH LITERACY IN PATIENTS WITH CHRONIC MUSCULOSKELETAL PAIN UNDER THE NATIONAL HEALTH SYSTEM (SUS)
16. SIALOADENITE LINFOCÍTICA FOCAL EM PACIENTE HIV: INFECÇÃO PELO HIV OU DOENÇA DE SJÖGREN? CASE REPORT
17. POSITIVITY OF ANTI-LA/SSB ANTIBODIES IN SJÖGREN S DISEASE IS ASSOCIATED WITH EXTRA-GLANDULAR SYSTEMIC MANIFESTATION: RESULTS FROM THE THE BRAZILIAN SJÖGREN S DISEASE REGISTRY (REBRAS)
18. THE EFFECT OF ANTIMALARIALS ON THE RISK AND SEVERITY OF BACTERIAL, VIRAL, FUNGAL AND SYSTEMIC SPECIFIC INFECTIONS IN RHEUMATOID ARTHRITIS
19. MAJOR SALIVARY GLANDS ULTRASOUND PREDICTS MORE SYSTEMIC MANIFESTATION IN PATIENTS WITH SJÖGREN S DISEASE
20. EFFECTS OF MANUAL VAGUS NERVE THERAPY COMBINED WITH TRANSCRANIAL DIRECT CURRENT STIMULATION ON PAIN IN WOMEN WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL
21. Pesquisas em vacinas contra a Covid-19 de interesse para o sistema público de saúde: uma experiência de integração de instituições de ensino e pesquisa com o Sistema Único de Saúde do Brasil
22. Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients
23. Comparison Of The Immunogenicity Among Covid-19 Vaccines Chadox1, Coronavac Or Bnt162b2 In Systemic Lupus Erythematosus (Sle): A Prospective Cohort
24. ARTICULAR SYSTEMIC DISEASE ACTIVITY AT DIAGNOSIS IS ASSOCIATED WITH DAMAGE, FATIGUE, PAIN AND DRYNESS OVER TIME IN PRIMARY SJÖGREN’S SYNDROME
25. SAFETY OF THE CORONAVAC AND CHADOX 1 COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM SAFER STUDY
26. FATIGUE IS ASSOCIATED WITH SYMPTOMS, DEPRESSION, ANXIETY, SLEEPINESS AND DISEASE ACTIVITY IN PRIMARY SJÖGREN’S SYNDROME
27. Safety assessment of BNT162b2, SinoVac and ChAdOx1 vaccines in Systemic Lupus Erythematosus patients – Data from SAFER Study
28. DIFFICULT ACCESS TO PREVENTION AND DETECTION MEASURES OF COVID-19 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
29. VALIDITY AND RELIABILITY OF THE BRAZILIAN VERSION OF THE PRIMARY SJÖGREN’S SYNDROME QUESTIONNAIRE
30. IMMUNOGENICITY AND SAFETY OF THE CHADOX-1 COVID-19 VACCINE IN PATIENTS WITH AUTOIMMUNE DISEASES AND HEALTHY CONTROLS: DATA FROM SAFER STUDY
31. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis
32. REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
33. EVENTOS ADVERSOS ÀS VACINAS CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES DA SAÚDE
34. REATIVIDADE VACINAL E DURAÇÃO DE RESPOSTA IMUNE DA CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES
35. EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)
36. CORRELAÇÃO CLÍNICA COM REATIVIDADE IMUNE APÓS INFECÇÃO LEVE A MODERADA POR COVID-19 EM UMA COORTE DE TRABALHADORES DA SAÚDE
37. Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)
38. Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
39. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium
40. Clinical risk factors for predicting anti-Sars-Cov-2 antibody immunoreactivity duration after mild COVID-19 infection.
41. Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil).
42. Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort
43. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.